Skip to main content
Erschienen in: Diabetologia 5/2018

28.09.2017 | Review

Biomarkers of cardiovascular disease: contributions to risk prediction in individuals with diabetes

verfasst von: Katherine N. Bachmann, Thomas J. Wang

Erschienen in: Diabetologia | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular disease is a leading cause of death, especially in individuals with diabetes mellitus, whose risk of morbidity and mortality due to cardiovascular disease is markedly increased compared with the general population. There has been growing interest in the identification of biomarkers of cardiovascular disease in people with diabetes. The present review focuses on the current and potential contributions of these biomarkers to predicting cardiovascular risk in individuals with diabetes. At present, certain biomarkers and biomarker combinations can lead to modest improvements in the prediction of cardiovascular disease in diabetes beyond traditional cardiovascular risk factors. Emerging technologies may enable the discovery of novel biomarkers and generate new information about known biomarkers (such as new combinations of biomarkers), which could lead to significant improvements in cardiovascular disease risk prediction. A critical question, however, is whether improvements in risk prediction will affect processes of care and decision making in clinical practice, as this will be required to achieve the ultimate goal of improving clinical outcomes in diabetes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat The Emerging Risk Factors Collaboration (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222CrossRefPubMedCentral The Emerging Risk Factors Collaboration (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222CrossRefPubMedCentral
2.
Zurück zum Zitat Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2:120–126CrossRefPubMed Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2:120–126CrossRefPubMed
3.
Zurück zum Zitat Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed
4.
Zurück zum Zitat Scirica BM (2017) Use of biomarkers in predicting the onset, monitoring the progression, and risk stratification for patients with type 2 diabetes mellitus. Clin Chem 63:186–195CrossRefPubMed Scirica BM (2017) Use of biomarkers in predicting the onset, monitoring the progression, and risk stratification for patients with type 2 diabetes mellitus. Clin Chem 63:186–195CrossRefPubMed
5.
Zurück zum Zitat St Clair L, Ballantyne CM (2007) Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am J Cardiol 99:80B–88BCrossRefPubMed St Clair L, Ballantyne CM (2007) Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am J Cardiol 99:80B–88BCrossRefPubMed
7.
Zurück zum Zitat Echouffo-Tcheugui JB, Kengne AP (2013) On the importance of global cardiovascular risk assessment in people with type 2 diabetes. Prim Care Diabetes 7:95–102CrossRefPubMed Echouffo-Tcheugui JB, Kengne AP (2013) On the importance of global cardiovascular risk assessment in people with type 2 diabetes. Prim Care Diabetes 7:95–102CrossRefPubMed
8.
Zurück zum Zitat Scirica BM, Bhatt DL, Braunwald E et al (2016) Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 1:989–998CrossRefPubMed Scirica BM, Bhatt DL, Braunwald E et al (2016) Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 1:989–998CrossRefPubMed
9.
Zurück zum Zitat van Dieren S, Beulens JW, Kengne AP et al (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98:360–369CrossRefPubMed van Dieren S, Beulens JW, Kengne AP et al (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98:360–369CrossRefPubMed
10.
Zurück zum Zitat D’Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117:743–753CrossRefPubMed D’Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117:743–753CrossRefPubMed
11.
Zurück zum Zitat Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study Group (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study Group (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef
12.
Zurück zum Zitat Kengne AP, Patel A, Colagiuri S et al (2010) The Framingham and UK prospective diabetes study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the action in diabetes and vascular disease: Preterax and Diamicron-MR controlled evaluation (ADVANCE) study. Diabetologia 53:821–831CrossRefPubMed Kengne AP, Patel A, Colagiuri S et al (2010) The Framingham and UK prospective diabetes study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the action in diabetes and vascular disease: Preterax and Diamicron-MR controlled evaluation (ADVANCE) study. Diabetologia 53:821–831CrossRefPubMed
13.
Zurück zum Zitat Davis WA, Colagiuri S, Davis TM (2009) Comparison of the Framingham and United Kingdom prospective diabetes study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle diabetes study. Med J Aust 190:180–184PubMed Davis WA, Colagiuri S, Davis TM (2009) Comparison of the Framingham and United Kingdom prospective diabetes study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle diabetes study. Med J Aust 190:180–184PubMed
14.
15.
Zurück zum Zitat Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935 Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935
16.
Zurück zum Zitat Ware JH (2006) The limitations of risk factors as prognostic tools. N Engl J Med 355:2615–2617CrossRefPubMed Ware JH (2006) The limitations of risk factors as prognostic tools. N Engl J Med 355:2615–2617CrossRefPubMed
17.
Zurück zum Zitat Looker HC, Colombo M, Agakov F et al (2015) Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia 58:1363–1371CrossRefPubMed Looker HC, Colombo M, Agakov F et al (2015) Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia 58:1363–1371CrossRefPubMed
18.
Zurück zum Zitat Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O (2005) Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48:156–163CrossRefPubMed Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O (2005) Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48:156–163CrossRefPubMed
19.
Zurück zum Zitat Gerstein HC, Pare G, McQueen MJ et al (2015) Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia. Circulation 132:2297–2304CrossRefPubMed Gerstein HC, Pare G, McQueen MJ et al (2015) Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia. Circulation 132:2297–2304CrossRefPubMed
20.
Zurück zum Zitat Hillis GS, Welsh P, Chalmers J et al (2014) The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 37:295–303CrossRefPubMed Hillis GS, Welsh P, Chalmers J et al (2014) The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 37:295–303CrossRefPubMed
21.
Zurück zum Zitat Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH (2006) Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49:2256–2262CrossRefPubMed Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH (2006) Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49:2256–2262CrossRefPubMed
22.
Zurück zum Zitat Bruno G, Landi A, Barutta F et al (2013) N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care 36:2677–2682CrossRefPubMedCentralPubMed Bruno G, Landi A, Barutta F et al (2013) N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care 36:2677–2682CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Hendriks SH, van Dijk PR, van Hateren KJ et al (2016) High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37). Am Heart J 174:43–50CrossRefPubMed Hendriks SH, van Dijk PR, van Hateren KJ et al (2016) High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37). Am Heart J 174:43–50CrossRefPubMed
25.
Zurück zum Zitat Landman GW, Kleefstra N, Groenier KH et al (2016) Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27). Atherosclerosis 250:46–51CrossRefPubMed Landman GW, Kleefstra N, Groenier KH et al (2016) Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27). Atherosclerosis 250:46–51CrossRefPubMed
26.
Zurück zum Zitat Alshehry ZH, Mundra PA, Barlow CK et al (2016) Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation 134:1637–1650CrossRefPubMed Alshehry ZH, Mundra PA, Barlow CK et al (2016) Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation 134:1637–1650CrossRefPubMed
27.
Zurück zum Zitat Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426CrossRefPubMed Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426CrossRefPubMed
28.
Zurück zum Zitat Meerwaldt R, Graaff R, Oomen PH et al (2004) Simple non-invasive assessment of advanced glycation end product accumulation. Diabetologia 47:1324–1330CrossRefPubMed Meerwaldt R, Graaff R, Oomen PH et al (2004) Simple non-invasive assessment of advanced glycation end product accumulation. Diabetologia 47:1324–1330CrossRefPubMed
29.
Zurück zum Zitat Moons KG, Kengne AP, Grobbee DE et al (2012) Risk prediction models: II. external validation, model updating, and impact assessment. Heart 98:691–698CrossRefPubMed Moons KG, Kengne AP, Grobbee DE et al (2012) Risk prediction models: II. external validation, model updating, and impact assessment. Heart 98:691–698CrossRefPubMed
30.
Zurück zum Zitat Moons KG, Altman DG, Vergouwe Y, Royston P (2009) Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338:b606 Moons KG, Altman DG, Vergouwe Y, Royston P (2009) Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338:b606
31.
Zurück zum Zitat Reilly BM, Evans AT (2006) Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med 144:201–209 Reilly BM, Evans AT (2006) Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med 144:201–209
32.
Zurück zum Zitat Authors/Task Force Members, Ryden L, Grant PJ et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087CrossRef Authors/Task Force Members, Ryden L, Grant PJ et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087CrossRef
33.
Zurück zum Zitat Stone NJ, Robinson JG, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 129:S1–S45CrossRefPubMed Stone NJ, Robinson JG, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 129:S1–S45CrossRefPubMed
34.
Zurück zum Zitat Anand SS, Dagenais GR, Mohan V et al (2012) Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 19:755–764CrossRefPubMed Anand SS, Dagenais GR, Mohan V et al (2012) Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 19:755–764CrossRefPubMed
35.
Zurück zum Zitat Echouffo-Tcheugui JB, Dieffenbach SD, Kengne AP (2013) Added value of novel circulating and genetic biomarkers in type 2 diabetes prediction: a systematic review. Diabetes Res Clin Pract 101:255–269CrossRefPubMed Echouffo-Tcheugui JB, Dieffenbach SD, Kengne AP (2013) Added value of novel circulating and genetic biomarkers in type 2 diabetes prediction: a systematic review. Diabetes Res Clin Pract 101:255–269CrossRefPubMed
37.
Zurück zum Zitat Singh AK, Singh R (2017) SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. Expert Rev Clin Pharmacol 10:429–442CrossRefPubMed Singh AK, Singh R (2017) SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. Expert Rev Clin Pharmacol 10:429–442CrossRefPubMed
38.
Zurück zum Zitat Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMed Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMed
39.
Zurück zum Zitat Echouffo-Tcheugui JB, Ogunniyi MO, Kengne AP (2011) Estimation of absolute cardiovascular risk in individuals with diabetes mellitus: rationale and approaches. ISRN Cardiol 2011:242656CrossRefPubMedCentralPubMed Echouffo-Tcheugui JB, Ogunniyi MO, Kengne AP (2011) Estimation of absolute cardiovascular risk in individuals with diabetes mellitus: rationale and approaches. ISRN Cardiol 2011:242656CrossRefPubMedCentralPubMed
40.
Zurück zum Zitat Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233–240CrossRefPubMed Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233–240CrossRefPubMed
41.
Zurück zum Zitat Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431CrossRefPubMed Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431CrossRefPubMed
42.
Zurück zum Zitat Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ (2009) Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 52:2001–2014CrossRefPubMedCentralPubMed Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ (2009) Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 52:2001–2014CrossRefPubMedCentralPubMed
43.
Zurück zum Zitat Kengne AP, Patel A, Marre M et al (2011) Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil 18:393–398CrossRefPubMed Kengne AP, Patel A, Marre M et al (2011) Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil 18:393–398CrossRefPubMed
44.
Zurück zum Zitat Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European prospective investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209–1216CrossRefPubMed Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European prospective investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209–1216CrossRefPubMed
45.
Zurück zum Zitat Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165:1910–1916CrossRefPubMed Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165:1910–1916CrossRefPubMed
46.
Zurück zum Zitat Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S (2012) Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care 35:396–403CrossRefPubMedCentralPubMed Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S (2012) Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care 35:396–403CrossRefPubMedCentralPubMed
47.
Zurück zum Zitat Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD (2013) Fibrinogen and future cardiovascular disease in people with diabetes: aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies. Diab Vasc Dis Res 10:143–151CrossRefPubMed Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD (2013) Fibrinogen and future cardiovascular disease in people with diabetes: aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies. Diab Vasc Dis Res 10:143–151CrossRefPubMed
48.
Zurück zum Zitat Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD (2012) Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British health surveys. J Hepatol 57:1083–1089CrossRefPubMed Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD (2012) Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British health surveys. J Hepatol 57:1083–1089CrossRefPubMed
49.
Zurück zum Zitat Pena MJ, Jankowski J, Heinze G et al (2015) Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens 33:2123–2132CrossRefPubMed Pena MJ, Jankowski J, Heinze G et al (2015) Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens 33:2123–2132CrossRefPubMed
Metadaten
Titel
Biomarkers of cardiovascular disease: contributions to risk prediction in individuals with diabetes
verfasst von
Katherine N. Bachmann
Thomas J. Wang
Publikationsdatum
28.09.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 5/2018
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4442-9

Weitere Artikel der Ausgabe 5/2018

Diabetologia 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.